Jeffrey M. Slezak

Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcome

John F. Ward, Jeffrey M. Slezak, Michael L. Blute et al. · British Journal of Urology · 2005 · 484 citations

Medicine, Oncology, Surgery +14

LONG-TERM HAZARD OF PROGRESSION AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER: CONTINUED RISK OF BIOCHEMICAL FAILURE AFTER 5 YEARS

Christopher L. Amling, Michael L. Blute, Erik J. Bergstralh et al. · The Journal of Urology · 2000 · 359 citations

Medicine, Surgery, Urology +8

DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?

Christopher L. Amling, Erik J. Bergstralh, Michael L. Blute et al. · The Journal of Urology · 2001 · 348 citations

Medicine, Oncology, Urology +13

Pyridostigmine Treatment Trial in Neurogenic Orthostatic Hypotension

Wolfgang Singer, Paola Sandroni, Tonette L. Opfer‐Gehrking et al. · Archives of Neurology · 2006 · 270 citations

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy of Contralateral Prophylactic Mastectomy in Women With a Personal and Family History of Breast Cancer

Shannon K. McDonnell, Daniel J. Schaid, Jeffrey L. Myers et al. · Journal of Clinical Oncology · 2001 · 264 citations

Medicine, Oncology, Breast Oncology +12